View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Theme
  2. Macro
  3. Covid-19
May 19, 2020

Firms may find it ‘difficult’ to co-market combined Covid-19 drugs

By Jamie Bell

Companies such as Gilead Sciences and Eli Lilly working together to develop combined Covid-19 treatments will find it “difficult” to co-market drugs, says an analyst.

The two firms, which are investigating a combination of remdesivir and baricitinib (Olumiant) to treat severely ill coronavirus patients, may face challenges further down the line — especially because these medicines cannot be integrated into a single regimen.

Read the full article here.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena